Skip to main content

Etudes cliniques en cours

Découvrez ici la liste des différentes études cliniques en cours classées par centre.

CHU Liège

  • PDC –LUNG-101 : An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)
  • REALEC : A multicenter non-interventional cohort study to evaluate the realworld clinical management and outcomes of patients diagnosed with ALK-positive advanced NSCLC treated with ALECTINIB (REALEC)
  • MARIPOSA-2 : A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure)
  • CARMEN EFC158-58 : Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic nonsquamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
  • CA001-050: A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
  • ETOP 13-18 BEAT-meso : A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma
  • Amgen 20190288 (ouverture mars 2022) : A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-Line Treatment (CodeBreaK 201)
  • AEGAN : A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
  • LUMINOSITY : A Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

CHU Mont-Godinne

Etudes sponsorisées interventionnelles en cours:

  • PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
  • Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.

Etudes sponsorisées non interventionnelles en cours:

  • BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.

Etudes académiques non interventionnelles en cours:

  • ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.

Cliniques Universitaires Saint-Luc

Etudes Onco en cours

1st line
Acronyme
Studies
Cancer
PI
BO29554 study (B-FAST)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial)
NSCLC (ROS+) A venir: BRAF V600+
P.C
ADRIATIC (D933QC00001)
Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)
SCLC limités post-chimioradio
T.P
ANAM 17-21
A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC
NSCLC cachexia
T.P
Zenith20 (Spectrum) (SPI-POZ-202)
Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)
NSCLC IV EGFR ou HER2 exon 20 inser/mut
T.P
CA209-73L
A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC)
NSCLC IIIA/B/C
TP
2nd line
ImmunoSABR
Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer
NSCLC IV
X.G
AMG510 (20190009)
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
NSCLC KRAS p.G12C
ThP
≥ 3rd line
ImmunoSABR
Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer
NSCLC IV
X.G
Autres
Acronyme
Studies
Cancer
PI
EORTC: E2-Radiate 1811
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
Tous cancers oligométa traités par Rth
XG
PACIFIC R D4194R00005
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
NSCLC stage III with durvalumab post chimioradio
T.P
Immuno Poumon
Etude prospective des facteurs pronostics et prédictifs de l'immunothérapie dans le cancer du poumon
NSCLC
FAb
SPECTA
Screening Cancer Patients for Efficient Clinical Trial Access
NSCLC IV naïfs/ thymomes, mésothéliome IV naïfs
T.P

Grand Hôpital de Charleroi (GHdC)

Faites défiler le tableau de gauche à droite pour découvrir l'entièreté des colonnes.
PathologiesEtudes-NomEtudes-CodeEudractNCTIPTitreType de SponsorPhaseStatutPINumero Interne EtudeGHDC
Poumons et Thorax
849-012 (Krystal program)
MRT 849-012
NCT04685135
MRTX849 (KRAS G12C inhibitor)
A randomized Phase 3 study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Firme
Phase 3
Ouverte à l'inclusion
Canon Jean-Luc
2020-ONCOHEMA-0094
Poumons et Thorax
PACIFIC-4
D9103C00001
2018-002572-41
NCT03833154
Durvalumab
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Firme
Phase 3
Ouverte à l'inclusion
Colinet Benoît
2019-ONCOHEMA-0111
Poumons et Thorax
PDC-Lung-101
PDC-Lung-101
2018-002382-19
NCT03970746
PDC*lung01
An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC)
Firme
Phase 1a
Ouverte à l'inclusion
Colinet Benoît
2018-ONCOHEMA-0159
Poumons et Thorax
MK7339-013
MK7339-013
2019-003616-31
NCT04624204
Pembrolizumab (MK-3475)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Firme
Phase 3
Ouverte à l'inclusion
Colinet Benoît
2019-ONCOHEMA-0202
Poumons et Thorax
Skyscraper 03
GO41854
2019-0044773-29
NCT04513925
Tiragolumab
A phase 3, open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in patients with locally advanced, unresectable stage 3 non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation.
Firme
Phase 3
Ouverte à l'inclusion
Colinet Benoît
2020-ONCOHEMA-0014
Poumons et Thorax
CA001-050
CA001-050
NCT04702880
BMS-986012
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Firme
Phase 2
Ouverte à l'inclusion
Colinet Benoît
2020-ONCOHEMA-0256
Poumons et Thorax
Mariposa-2
61186372NSC3002
2021-001825-33
NCT04988295
Amivantamab
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
Firme
Phase 3
Ouverte à l'inclusion
Colinet Benoît
2021-ONCOHEMA-0042
Poumons et Thorax
Tropion-Lung08
SH 7024395 / DS1062-A-U304 / Keynote-C73
2021-002555-10
NCT05215340
Datopotomab deruxtecan (Dato-DXd) (bispécifique anti TROP-2)
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-LUNG08)
Firme
Phase 3
Ouverture prochaine
Colinet Benoît
2021-ONCOHEMA-0082
Toutes Tumeurs
GO40311
GO40311
2019-004596-39
NCT03448042
BTRC4017A (humanized, full lenght IgG1 anti HER2 / cluster if differentiation 3 (CD3) T cell-dependent bispecific antibody)
A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCER
Firme
Phase 1
Ouverte à l'inclusion
Canon Jean-Luc
2020-ONCOHEMA-0098
Toutes Tumeurs
Precision 2 – Olaparib
1-2018 BSMO
2018-002966-37
NCT03967938
Olaparib (inhibiteurs de PARP)
Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. SAUF SEIN, OVAIRE, PROSTATE, ATM gene
Académique
Phase 2
Ouverte à l'inclusion
Canon Jean-Luc
2019-ONCOHEMA-0093
Toutes Tumeurs
Precision 1
BSMO 2014-2
NCT03873103
The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment “PRECISION 1”
Académique
Prospective-Collection d'échantillons
Ouverte à l'inclusion
Canon Jean-Luc
2020-ONCOHEMA-0022
Toutes Tumeurs
TAPISTRY
BO41932
2020-001847-16
NCT04589845
Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in patients with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by an next-generation-sequencing (NGS) assay
Firme
Phase 2
Ouverte à l'inclusion
Canon Jean-Luc
2020-ONCOHEMA-0028
Toutes Tumeurs
DF1001-001
DF1001-001
2019-004706-10
NCT04143711
DF1001 (first-in-class HER2-targeted immunotherapy)
A phase I/II, first-in-human, multi-part, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of DF1001 in patients with locally advanced or metastatic solid tumors, and expansion in selected indications
Firme
Phase 2
Ouverte à l'inclusion
Canon Jean-Luc
2020-ONCOHEMA-0013
Toutes Tumeurs
BALLETT
BSMO2020-2
NCT05058937
A study to examine the clinical value of comprehensive genomic profiling performed by Belgian NGS laboratories: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre - Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT)
Académique
Prospective-Collection d'échantillons
Ouverte à l'inclusion
Canon Jean-Luc
2020-ONCOHEMA-0128
Toutes Tumeurs
SGNTUC-019
SGNTUC-019
NCT04579380
Tucatinib (tyrosine kinase réversible, ciblant l'HER2)
A phase 2 basket study of Tucatinib in combination with Trastuzumab in subjects with previously treated, locally advanced unresectable or metastatic solid tumors driven by HER2 alterations
Firme
Phase 2
Ouverte à l'inclusion
Canon Jean-Luc
2020-ONCOHEMA-0238
Toutes Tumeurs
B9991046
B9991046
2021-002457-29
NCT05059522
Avelumab
Avelumab master protocol: An open-label continuation study for participants continuing from Pfizer-sponsored avelumab clinical studies.
Firme
Phase 3
Ouverte à l'inclusion
Canon Jean-Luc
2021-ONCOHEMA-0121
Toutes Tumeurs
FORTITUDE-301
20210104
NCT05325866
Bemarituzumab (AMG552) (anti-FGFR2b antibody)
A phase 1b/2, multicenter, open-label basket study evaluating the safety and efficacy of bemarituzumab monotherapy in solid tumors with FGFR2b overexpression (FORTITUDE-301)
Firme
Phase 1b Phase 2
Ouverte à l'inclusion
Schroder David
2022-ONCOHEMA-0010
Toutes Tumeurs
Tropics-3
IMMU-132-11
NCT03964727
IMMU-132 (Sacituzumab govitecan)
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
Firme
Phase 2
Ouverte à l'inclusion
Schroder David
2019-ONCOHEMA-0030
Toutes Tumeurs
TAK-981-1002
TAK-981-1002
2020-003947-27
NCT03648372
TAK-981 (inhibitor of the SUMOylation enzymatic cascade with potential immune-activating and antineoplastic activities)
An open label, dose-escalation, phase 1/2 study to revaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of TAK-981 in adult patients with advanced or metastatic solid tumors or relapsed/refractory hematologic malignancies and in a subset with coronavirus disease 2019
Firme
Phase 1 Phase 2
Ouverte à l'inclusion
Schroder David
2020-ONCOHEMA-0245